RxDoctor Payments Data

Giri Tummuru, MD

Internal Medicine · Montclair, CANPI 1467625277

Payments from drug & device makers

$1,851in general payments, 2019–2025

Across 89 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$527
  • Johnson & Johnson$327
  • Novartis$263
  • AstraZeneca$136
  • Jazz Pharmaceuticals Inc.$123
  • Pfizer$121
  • plus $355 from 9 others

What the payments were for

  • Food & beverage$1,851100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,851 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$213,375
Medicare patients
402
Services billed
1,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$30,746
FarxigaDapagliflozin Propanediol35$12,319
OzempicSemaglutide11$11,414
JardianceEmpagliflozin23$8,496
CreonLipase/Protease/Amylase17$6,721
EntrestoSacubitril/Valsartan19$6,484
XareltoRivaroxaban19$6,074
Praluent PenAlirocumab18$5,435
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$4,405
DapagliflozinDapagliflozin Propanediol18$4,291
BrilintaTicagrelor14$3,539
Insulin Lispro Kwikpen U-100Insulin Lispro22$2,199
Gabapentin97$2,162
SteglatroErtugliflozin Pidolate14$2,105
Atorvastatin Calcium139$2,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$30,74689 claims
AstraZenecaFarxiga, Brilinta$136$15,85849 claims
Boehringer IngelheimJardiance$32$8,49623 claims
AbbVieCreon$21$6,72117 claims
NovartisEntresto$263$6,48419 claims
Johnson & JohnsonXarelto$327$6,07419 claims
MerckSteglatro$43$2,10514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Montclair

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →